Immunology · 2018 · 50 citations · 18 references
MedicineMolecular BiologyOncologyCarcinogenesisMolecular OncologyTumor ProgressionCancer BiomarkersCancer ProgressionColorectal CancerMyeloid-derived Suppressor CellsSignal Transduction In CancerTumor Suppressor GenesColorectal Cancer PathologyCox RegressionMyeloid-derived Suppressor Cell ExpansionMyeloid-derived Suppressor Cell FunctionMyeloid-derived Suppressor Cell MarkersMyeloid-derived Suppressor Cell Signaling PathwaysPten InactivationTumor Suppressor Pathways
Summary The expansion of myeloid‐derived suppressor cells (MDSCs) correlates with tumorigenesis in colorectal cancer (CRC). Here, we found a significant association between CD33 + MDSC number and Yes‐associated protein 1 (YAP1) and phosphatase and tensin homologue (PTEN) levels in CRC patients ( P < 0·05). Moreover, the CD33 + MDSCs, YAP1 and PTEN were identified as predictors for the prognosis of CRC patients ( P < 0·05). Notably, CD33 + MDSCs were an independent survival predictor for CRC patients through a Cox model analysis. In vitro data determined that the expression levels of YAP1 and PTEN in CRC‐derived cell lines were associated with CRC‐derived MDSC induction, and the blockade of YAP1 and PTEN decreased CRC‐derived MDSC induction. A mechanistic analysis revealed that YAP1 promoted CRC‐derived MDSC induction by suppressing PTEN expression to up‐regulate COX‐2, P‐AKT and P‐p65 in CRC‐derived cells, leading to secretion of the cytokine granulocyte–macrophage colony‐stimulating factor. Our findings establish a novel mechanism of pro‐tumorigenic MDSC induction mediated by ectopic YAP1 and PTEN expression in CRC.
18
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng, Jie Qing Chen, Chengwen Liu et al. · Cancer Discovery · 2015 · 1.5K citations · Full text
Medicine, Immunology, Oncology +17
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Guocan Wang, Xin Lü, Prasenjit Dey et al. · Cancer Discovery · 2015 · 553 citations · Full text
Medicine, Cancer Biology, Oncology +17